The impact of HPV/HIV co-infection on immunosuppression, HPV genotype, and cervical cancer biomarkers

Background Human papillomavirus (HPV) and human immunodeficiency virus (HIV) co-infection present a significant impact on women's health globally, especially in immunocompromised individuals. HIV-induced immunosuppression promotes the persistence of high-risk HPV infection and increased the pro...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMC Cancer 2025, Vol.25 (1)
Hauptverfasser: Swase, Terkimbi Dominic, Fasogbon, Ilemobayo Victor, Eseoghene, Ifie Josiah, Etukudo, Ekom Monday, Mbina, Solomon Adomi, Joan, Chebet, Dangana, Reuben Samson, Anyanwu, Chinyere, Vandu, Comfort Danchal, Agbaje, A. B, Shinkafi, Tijjani Salihu, Abubarkar, Ibrahim Babangida, Aja, Patrick Maduabuchi
Format: Report
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Human papillomavirus (HPV) and human immunodeficiency virus (HIV) co-infection present a significant impact on women's health globally, especially in immunocompromised individuals. HIV-induced immunosuppression promotes the persistence of high-risk HPV infection and increased the progression to cervical cancer. The aim of this systematic review was to assessed the impact of HPV/HIV co-infection on the prevalence and distribution of HR-HPV genotypes, the level of immunosuppression and expression of cervical cancer biomarkers. Method The article selection method for this review was based on the 2020 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards. The total of eighty-four (84) articles from standard electronic databases mainly Web of Science, PubMed, and Scopus were extracted and reviewed. The articles were published in English between 2008 and 2024 and comprised a total of 80023 participants. Results The HR-HPV genotypes reported across various studies include HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 54, 56, 58, 59, 66, 68, 70, 73, and 82. Among HIV positive individuals, the most common circulating HR-HPV genotypes were HPV16, 18, 45, 35, and 58, accounted for 11%, 10%, 9%, 8%, and 8% of cases, respectively. Approximately 29.1% and 30.0% of patients had CD4 counts of 200-400 cells/L and 300-400 cells/L, respectively. The most commonly reported cervical cancer biomarkers were p16INK4a and Ki-67, according to the analysis. Conclusion The findings indicate high prevalence of multiple HR-HPV genotypes among HIV positive individuals, indicating the impact of HPV/HIV co-infection on immunosuppression and persistence of HPV infection. The expression of cervical cancer biomarker such as p16INK4a and Ki-67 emphasized target screening and early detection strategy in high-risk population. However, there was no direct impact of HPV/HIV co-infection reported on these biomarkers and required to be studied more especially in people living with HIV. Keywords: Human papillomavirus, Human immunodeficiency virus, Immunosuppression, Cervical cancer Biomarkers, Genotypes
ISSN:1471-2407
1471-2407
DOI:10.1186/s12885-025-13516-2